Treatment decisions and outcomes in two patients with therapy-related acute myeloid leukemia (t-AML).
| Patient . | Decision . | Outcome . |
|---|---|---|
| #1 | Recommended to continue to receive 4 courses of high-dose cytarabine as standard consolidation for her t-AML with inv(16). G-CSF was not recommended. Allogeneic transplantation was not recommended in first CR because of favorable cytogenetics and the lack of an identically matched donor. | In remission for over 2 years |
| #2 | Allogeneic HCT from an HLA-matched unrelated donor was recommended because of patient’s younger age, good performance status, prior autologous transplantation, and unfavorable cytogenetics (monosomy 7). | Uncomplicated post-transplantation course, achieved full donor chimerism, has remained in CR for more than 3 years |
| Patient . | Decision . | Outcome . |
|---|---|---|
| #1 | Recommended to continue to receive 4 courses of high-dose cytarabine as standard consolidation for her t-AML with inv(16). G-CSF was not recommended. Allogeneic transplantation was not recommended in first CR because of favorable cytogenetics and the lack of an identically matched donor. | In remission for over 2 years |
| #2 | Allogeneic HCT from an HLA-matched unrelated donor was recommended because of patient’s younger age, good performance status, prior autologous transplantation, and unfavorable cytogenetics (monosomy 7). | Uncomplicated post-transplantation course, achieved full donor chimerism, has remained in CR for more than 3 years |